KEY RESULTS
Ixazomib significantly inhibited the proliferation and induced apoptosis
in ESCC cells. RT-PCR results showed that the expression of endoplasmic
reticulum stress-related gene NOXA and c-Myc significant increase after
treatment with ixazomib in ESCC cell. Then we knockdown the NOXA and
c-Myc by siRNA, the therapeutic effect of ixazomib markedly decrease,
which confirmed that c-Myc/NOXA pathway played a key role in the
treatment of ESCC with ixazomib. In vivo, the xenograft ESCC model mice
were given 10 mg/kg of ixazomib every other day for 30 days. The results
showed that the tumor size in the treatment group was significantly
smaller than the control group